Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain.

Animals Female Male Mice Analgesics / pharmacology Carrageenan / adverse effects Hyperalgesia / chemically induced Pain / drug therapy Receptor, Cannabinoid, CB1 Receptor, Cannabinoid, CB2 / genetics Receptors, Cannabinoid Sensory Receptor Cells
CB(2) receptor Cannabinoid Dorsal root ganglion Inflammation Pain

Journal

Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217

Informations de publication

Date de publication:
01 10 2023
Historique:
received: 30 11 2022
revised: 18 05 2023
accepted: 23 05 2023
pmc-release: 01 10 2024
medline: 14 7 2023
pubmed: 8 6 2023
entrez: 7 6 2023
Statut: ppublish

Résumé

CB

Identifiants

DOI: 10.1016/j.neuropharm.2023.109601 PMID: 37286073 PMC: PMC10409300
pubmed: 37286073
pii: S0028-3908(23)00191-0
doi: 10.1016/j.neuropharm.2023.109601
pmc: PMC10409300
mid: NIHMS1909189
pii:
doi:

Substances chimiques

Analgesics 0
Carrageenan 9000-07-1
Receptor, Cannabinoid, CB1 0
Receptor, Cannabinoid, CB2 0
Receptors, Cannabinoid 0
Cnr2 protein, mouse 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109601

Subventions

Organisme : NIDA NIH HHS
ID : P01 DA009158
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA041229
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA047858
Pays : United States
Organisme : NIDA NIH HHS
ID : R21 DA042584
Pays : United States

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None

Références

Sci Transl Med. 2022 Feb 16;14(632):eabj8186
pubmed: 35171654
Biol Psychiatry. 2015 Mar 1;77(5):475-87
pubmed: 24853387
Br J Pharmacol. 1996 Jun;118(4):829-38
pubmed: 8799551
Chem Phys Lipids. 2002 Dec 31;121(1-2):191-200
pubmed: 12505700
Neuropharmacology. 2005 Apr;48(5):658-72
pubmed: 15814101
Neuroscience. 2003;119(3):747-57
pubmed: 12809695
J Pharmacol Exp Ther. 2004 Feb;308(2):446-53
pubmed: 14610224
Nature. 1993 Sep 2;365(6441):61-5
pubmed: 7689702
Eur J Pain. 2018 Mar;22(3):471-484
pubmed: 29160600
ACS Pharmacol Transl Sci. 2019 Oct 01;2(6):414-428
pubmed: 32259074
Pharmacol Res. 2023 Jan;187:106560
pubmed: 36417942
Expert Opin Ther Targets. 2021 Aug;25(8):659-676
pubmed: 34424117
Neuroscience. 2003;120(1):155-62
pubmed: 12849749
J Med Chem. 2013 Jul 25;56(14):5722-33
pubmed: 23795771
Immunity. 2013 Jan 24;38(1):79-91
pubmed: 23273845
eNeuro. 2017 Mar 13;4(1):
pubmed: 28303259
Eur J Pharmacol. 2020 Nov 5;886:173544
pubmed: 32896549
Pain. 2002 Apr;96(3):253-260
pubmed: 11972997
Science. 2005 Oct 14;310(5746):329-32
pubmed: 16224028
J Pathol. 1971 May;104(1):15-29
pubmed: 4398139
Br J Pharmacol. 2011 Jan;162(2):428-40
pubmed: 20880025
Eur J Biochem. 1995 Aug 15;232(1):54-61
pubmed: 7556170
Pain. 2011 Sep;152(9):1976-1987
pubmed: 21550725
Pain. 2021 Jul 1;162(Suppl 1):S26-S44
pubmed: 33729209
Br J Pharmacol. 2008 Jan;153(2):319-34
pubmed: 17994113
Neuroscience. 2003;117(3):659-70
pubmed: 12617970
Proc Soc Exp Biol Med. 1962 Dec;111:544-7
pubmed: 14001233
J Neuroimmune Pharmacol. 2015 Jun;10(2):318-32
pubmed: 25980325
J Neurophysiol. 2004 Dec;92(6):3562-74
pubmed: 15317842
Pain. 2005 Dec 5;118(3):327-335
pubmed: 16289798
Nat Neurosci. 2011 Jul 24;14(9):1160-6
pubmed: 21785434
J Neuroinflammation. 2018 May 24;15(1):158
pubmed: 29793509
Pain. 2022 May 1;163(5):834-851
pubmed: 35001054
Pharmacol Rev. 2002 Jun;54(2):161-202
pubmed: 12037135
Anesthesiology. 2003 Oct;99(4):955-60
pubmed: 14508331
J Biol Chem. 2022 Jun;298(6):101999
pubmed: 35500651
Eur J Neurosci. 2006 Mar;23(6):1530-8
pubmed: 16553616
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Br J Pharmacol. 2007 Jan;150(2):153-63
pubmed: 17160008
Pain. 2008 Sep 15;138(3):667-680
pubmed: 18692962
eNeuro. 2018 Sep 13;5(5):
pubmed: 30221190
Mol Pharmacol. 2018 Feb;93(2):49-62
pubmed: 29192123
Mediators Inflamm. 2020 Apr 15;2020:8508906
pubmed: 32377166
Proc Natl Acad Sci U S A. 2010 May 18;107(20):9424-9
pubmed: 20439739
Recent Pat CNS Drug Discov. 2013 Apr;8(1):42-69
pubmed: 23477308
Int Rev Psychiatry. 2009 Apr;21(2):104-12
pubmed: 19367504
Neuroscience. 2005;135(1):235-45
pubmed: 16084654
Palliat Med. 2004 Jan;18(1):5-11
pubmed: 14982201
Pain. 2001 Sep;93(3):239-245
pubmed: 11514083
Neuroscience. 1999;92(4):1171-5
pubmed: 10426476
Phytother Res. 2009 May;23(5):646-50
pubmed: 19067390

Auteurs

Kelsey G Guenther (KG)

Program in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.

Zhili Xu (Z)

Program in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.

Julian Romero (J)

Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid, Spain.

Cecilia J Hillard (CJ)

Department of Pharmacology and Toxicology, Med. Col. of Wisconsin, Milwaukee, WI, USA.

Ken Mackie (K)

Program in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA; Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, USA.

Andrea G Hohmann (AG)

Program in Neuroscience, Indiana University, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA; Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, USA. Electronic address: hohmanna@indiana.edu.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Conditional deletion of CB2 cannabinoid...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Conditional deletion of CB2 cannabinoid...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Analgésiques › Conditional deletion of CB2 cannabinoid...
questionsmedicales.fr › Glucides › Polyosides › Carragénane › Conditional deletion of CB2 cannabinoid...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Troubles sensitifs › Troubles somatosensoriels › Hyperalgésie › Conditional deletion of CB2 cannabinoid...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Sensation › Douleur › Conditional deletion of CB2 cannabinoid...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs couplés aux protéines G › Récepteurs de cannabinoïdes › Récepteur cannabinoïde de type CB1 › Conditional deletion of CB2 cannabinoid...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs couplés aux protéines G › Récepteurs de cannabinoïdes › Récepteur cannabinoïde de type CB2 › Conditional deletion of CB2 cannabinoid...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs couplés aux protéines G › Récepteurs de cannabinoïdes › Conditional deletion of CB2 cannabinoid...
questionsmedicales.fr › Cellules › Neurones › Neurones afférents › Cellules réceptrices sensorielles › Conditional deletion of CB2 cannabinoid...